Abstract
IntroductionDespite the success of Faecal calprotectin (FC) as a biomarker in Inflammatory Bowel Disease (IBD), there appears to be practical issues with testing in clinical practice, including sample collection, delivery...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
